Showing 1 - 20 results of 2,096 for search '(( ct ((((largest decrease) OR (marked decrease))) OR (larger decrease)) ) OR ( 5 non decrease ))', query time: 0.66s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  13. 13
  14. 14
  15. 15

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the non-recurrence group, the respective preoperative treatment counts were 2.6 ± 1.1, 0.5 ± 0.9, 0.6 ± 0.9, 0.1 ± 0.3, and 3.8 ± 1.3, and no additional treatments were required during the 3 postoperative years. …”
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”